[{"id":"aea14076-21d7-468d-aaaf-017ccde487e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000754","created_at":"2021-01-29T06:52:32.200Z","updated_at":"2025-02-25T13:06:57.647Z","phase":"Phase 2","brief_title":"A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3","source_id_and_acronym":"NCT00000754","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 60","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 02/01/1995","study_completion_date":" 02/01/1995","last_update_posted":"2021-11-04"},{"id":"28e36f19-bd78-45d2-b015-7dbcf89dc3a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT00000764","created_at":"2021-01-29T06:52:33.349Z","updated_at":"2024-07-02T16:36:22.294Z","phase":"Phase 1","brief_title":"Chemoprevention of Anal Neoplasia Arising Secondary to Anogenital Human Papillomavirus Infection in Persons With HIV Infection.","source_id_and_acronym":"NCT00000764","lead_sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":" Completion: 07/01/1996","study_completion_date":" 07/01/1996","last_update_posted":"2021-10-28"},{"id":"fab262b8-124c-4663-b3ae-6f98de0eae86","acronym":"","url":"https://clinicaltrials.gov/study/NCT02174172","created_at":"2021-01-18T10:08:01.012Z","updated_at":"2024-07-02T16:36:45.116Z","phase":"Phase 1","brief_title":"A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT02174172","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF • ALK • PD-1","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • BRAF V600 • ALK rearrangement","tags":["BRAF • ALK • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • BRAF V600 • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • Gazyva (obinutuzumab) • Pegasys (pegylated interferon α -2a) • Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 158","initiation":"Initiation: 08/18/2014","start_date":" 08/18/2014","primary_txt":" Primary completion: 11/25/2019","primary_completion_date":" 11/25/2019","study_txt":" Completion: 11/25/2019","study_completion_date":" 11/25/2019","last_update_posted":"2020-05-12"},{"id":"4ac01f41-47c9-424d-8c92-8d8f714655fc","acronym":"SPIRIT","url":"https://clinicaltrials.gov/study/NCT00219739","created_at":"2022-04-24T08:54:17.322Z","updated_at":"2025-02-25T15:47:30.851Z","phase":"Phase 3","brief_title":"STI571 ProspectIve RandomIzed Trial: SPIRIT","source_id_and_acronym":"NCT00219739 - SPIRIT","lead_sponsor":"Poitiers University Hospital","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • cytarabine • Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 789","initiation":"Initiation: 09/01/2003","start_date":" 09/01/2003","primary_txt":" Primary completion: 12/01/2014","primary_completion_date":" 12/01/2014","study_txt":" Completion: 12/01/2014","study_completion_date":" 12/01/2014","last_update_posted":"2020-04-13"},{"id":"9ff98ed0-b100-49fd-8e72-92c3280d0736","acronym":"","url":"https://clinicaltrials.gov/study/NCT00006244","created_at":"2021-01-17T23:53:07.256Z","updated_at":"2024-07-02T16:37:20.013Z","phase":"Phase 2","brief_title":"Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma","source_id_and_acronym":"NCT00006244","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" IL2","pipe":"","alterations":" ","tags":["IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Intron A (interferon α-2b) • Proleukin (aldesleukin) • Roferon A (recombinant interferon alfa-2a)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 02/01/2000","start_date":" 02/01/2000","primary_txt":" Primary completion: 04/01/2016","primary_completion_date":" 04/01/2016","study_txt":" Completion: 04/01/2016","study_completion_date":" 04/01/2016","last_update_posted":"2017-07-12"}]